Thomas B Casale1, Eric D Bateman2, Mark Vandewalker3, J Christian Virchow4, Hendrik Schmidt5, Michael Engel6, Petra Moroni-Zentgraf7, Huib A M Kerstjens8. 1. Division of Allergy and Immunology, Morsani College of Medicine, University of South Florida, Tampa, Fla. Electronic address: tbcasale@health.usf.edu. 2. Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa. 3. Clinical Research of the Ozarks, Columbia, Mo. 4. University Clinic Rostock, Interdiszplinäre Internistische Intensivstation, Zentrum für Innere Medizin, Medizinische Klinik I, Rostock, Germany. 5. Global Biometrics and Data Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany. 6. TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany. 7. Medical Department, Boehringer Ingelheim Pty Ltd, Sydney, NSW, Australia. 8. Department of Pulmonary Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Abstract
BACKGROUND: Adding tiotropium to existing inhaled corticosteroid (ICS) maintenance therapy with or without a long-acting β2-agonist (LABA) has been shown to be beneficial in patients with symptomatic asthma. OBJECTIVE: To assess whether responses to tiotropium Respimat add-on therapy were influenced by patients' T2 status. METHODS: In this exploratory study, data from 4 phase III trials were analyzed: once-daily tiotropium 5 μg or placebo as add-on to ICS + LABA (PrimoTinA-asthma; 2 replicate trials; NCT00772538/NCT00776984; n = 912); once-daily tiotropium 5 μg or 2.5 μg, twice-daily salmeterol 50 μg, or placebo as add-on to ICS (MezzoTinA-asthma; 2 replicate trials; NCT01172808/NCT01172821; n = 2100). The prespecified efficacy outcomes of these studies have been reported previously. Here, further exploratory subgroup analyses were performed to study whether these coprimary end points were influenced by serum IgE levels, blood eosinophil counts, and clinician judgment of allergic asthma. In addition, for the continuous parameters, namely, IgE and blood eosinophils, their influence on the treatment effect was modeled over the whole range of values. RESULTS:Tiotropium was efficacious in improving peak FEV1 within 3 hours postdose and trough FEV1, independent of T2 status. Tiotropium significantly reduced the risk of severe asthma exacerbations and asthma worsening, independent of T2 phenotype; Cox regression modeling supported a beneficial effect of tiotropium on exacerbations, independent of IgE levels or eosinophil counts. Numerical improvements in the 7-question Asthma Control Questionnaire (ACQ-7) responder rate with tiotropium versus placebo were observed in T2high and T2low patients; logistic regression modeling provided further evidence for improvement in ACQ-7 responder rates with tiotropium, independent of IgE levels or eosinophil counts. CONCLUSIONS: The results of our exploratory analyses suggest that the improvements seen with tiotropium Respimat as add-on to ICS ± LABA in patients with symptomatic asthma on lung function, exacerbation risk, and symptom control are independent of T2 phenotype.
RCT Entities:
BACKGROUND: Adding tiotropium to existing inhaled corticosteroid (ICS) maintenance therapy with or without a long-acting β2-agonist (LABA) has been shown to be beneficial in patients with symptomatic asthma. OBJECTIVE: To assess whether responses to tiotropium Respimat add-on therapy were influenced by patients' T2 status. METHODS: In this exploratory study, data from 4 phase III trials were analyzed: once-daily tiotropium 5 μg or placebo as add-on to ICS + LABA (PrimoTinA-asthma; 2 replicate trials; NCT00772538/NCT00776984; n = 912); once-daily tiotropium 5 μg or 2.5 μg, twice-daily salmeterol 50 μg, or placebo as add-on to ICS (MezzoTinA-asthma; 2 replicate trials; NCT01172808/NCT01172821; n = 2100). The prespecified efficacy outcomes of these studies have been reported previously. Here, further exploratory subgroup analyses were performed to study whether these coprimary end points were influenced by serum IgE levels, blood eosinophil counts, and clinician judgment of allergic asthma. In addition, for the continuous parameters, namely, IgE and blood eosinophils, their influence on the treatment effect was modeled over the whole range of values. RESULTS:Tiotropium was efficacious in improving peak FEV1 within 3 hours postdose and trough FEV1, independent of T2 status. Tiotropium significantly reduced the risk of severe asthma exacerbations and asthma worsening, independent of T2 phenotype; Cox regression modeling supported a beneficial effect of tiotropium on exacerbations, independent of IgE levels or eosinophil counts. Numerical improvements in the 7-question Asthma Control Questionnaire (ACQ-7) responder rate with tiotropium versus placebo were observed in T2high and T2low patients; logistic regression modeling provided further evidence for improvement in ACQ-7 responder rates with tiotropium, independent of IgE levels or eosinophil counts. CONCLUSIONS: The results of our exploratory analyses suggest that the improvements seen with tiotropium Respimat as add-on to ICS ± LABA in patients with symptomatic asthma on lung function, exacerbation risk, and symptom control are independent of T2 phenotype.
Authors: Helena Donath; Sven Kluge; Georgia Sideri; Jordis Trischler; Silivija P Jerkic; Johannes Schulze; Stefan Zielen; Katharina Blumchen Journal: Front Pediatr Date: 2020-11-20 Impact factor: 3.418
Authors: Alan Kaplan; J Mark FitzGerald; Roland Buhl; Christian Vogelberg; Eckard Hamelmann Journal: NPJ Prim Care Respir Med Date: 2020-11-11 Impact factor: 2.871
Authors: Luis Pérez de Llano; Marc Miravitlles; Rafael Golpe; Francisco Javier Alvarez-Gutiérrez; Carolina Cisneros; Carlos Almonacid; Eva Martinez-Moragon; Francisco-Javier Gonzalez-Barcala; David Ramos-Barbón; Vicente Plaza; Jose Luis Lopez-Campos; Juan Pablo de-Torres; Ciro Casanova; Juan Luis Garcia Rivero; Juan Rodriguez Hermosa; Myriam Calle Rubio; Juan Jose Soler-Cataluña; Borja G Cosio Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-09-04